Materials and methods: Under observation were 60 patients who were hospitalized in the «Transcarpathian Regional Clinical Hospital named after Andrei Novak» with a diagnosis of
COPD II gr B in combination with
GERD and 36 patients diagnosed with
GERD who were treated on an outpatient basis. To study the effectiveness of antireflux
therapy and its impact on the course of
COPD, patients are divided into 2 groups: 1 group (main) (n = 60) - patients with
COPD in combination with
GERD, group 2 (control) (n = 36) - patients with isolated
GERD. Patients with positive Helicobacter pylori status received antihelicobacter
therapy. Patients in group 1 were divided into subgroups: 1a (n = 34) -
COPD in combination with esophageal manifestations of
GERD and 1b (n = 26) -
COPD in combination with extraesophageal manifestations of
GERD. Group 1a received complex
therapy, which consisted of basic
therapy of
COPD in combination with antireflux and with rebapimide, group 1b - only basic
therapy of
COPD in combination with antireflux.
RESULTS: Results:
After treatment, the clinical signs of
GERD significantly decreased in all patients receiving complex
therapy, improved the course of respiratory symptoms of
COPD.
After treatment, patients showed a clinically significant reduction in systemic
inflammation, which is best seen in the group with the use of rabipimide.
CONCLUSION: Conclusions: Comprehensive treatment of combined pathology with the use of antireflux
therapy has a positive effect not only on the clinical symptoms of the disease, but also on the indicators of external respiratory function in patients with combined
COPD and
GERD.